Navigation Links
CLIA Waiver Submitted for Rapid HIV Test Employs StatSure's 'Barrel' Technology
Date:8/19/2007

FRAMINGHAM, Mass., Aug. 14 /PRNewswire-FirstCall/ -- StatSure Diagnostic Systems, Inc. (OTC Bulletin Board: SSUR - News) is pleased to announce that its patented, "barrel- test" format for the detection of antibodies to HIV-1/2 in human whole blood, serum, and plasma has completed the trials needed for a CLIA waiver application and that the results have been submitted to the United States Food & Drug Administration (FDA) for their review. The Company believes the results of these trials were consistent or superior to those of other rapid point of care products that have received a CLIA waiver. The HIV 1/2 product is marketed and distributed worldwide by Inverness Medical Innovations (Amex: IMA) under its Clearview(R) brand as "Clearview COMPLETE HIV 1/2". If CLIA waiver were granted for this product, it would greatly expand the available market for this product in the U.S. There are approximately 189,000 testing sites across the United States, including doctors' offices and clinics that require a test to be CLIA waived before it can be used. The United States Centers for Disease Control recommends HIV testing as part of the routine medical care of most Americans. On May 25, 2006, this HIV 1/2 test received marketing approval from the United States Food and Drug Administration's (FDA) Center for Biologics and Research (CBER) -- a prerequisite to submitting the CLIA Waiver Application.

According to Steve Peltzman CEO of StatSure: "Having this product CLIA waived should begin to capture the commercial potential of this product and allow SDS to go forward with its plan to expand the use of this format to other infectious diseases and to establish new strategic partnerships."

About StatSure:

StatSure Diagnostic Systems, Inc. (OTC Bulletin Board: SSUR - News) is engaged in the development, manufacture and marketing of rapid immunoassay tests for the detection of sexually transmitted and other infectious diseases; in addition, the Company has developed and is marketing a product line of patented, oral- fluid collection devices. The Company's proprietary platforms provide significant customer benefits and competitive advantages as compared to similar products that are currently available. Improved accuracy, operator convenience, and reduced risk of infection from collecting and handling specimens, have been engineered into SDS products. All of the company's diagnostic tests are based on the same easy-to-use technology platform, thus facilitating the development of future products. Certain of these products are sold in the United States as well as internationally to various distributors for use in clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations.

Forward-Looking Statements

Statements contained herein that are not historical facts are forward- looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties.

Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing and the demand for the Company's products. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC").


'/>"/>
SOURCE StatSure Diagnostic Systems, Inc.

Copyright©2007 PR Newswire.

Related medicine technology :

1. Rapid Whole Blood Testing for Infectious Mononucleosis Antibodies
2. Rapid Flu Tests May Prove Especially Helpful This Season
3. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
4. Avian (Bird) Flu: Is There a Role for Rapid Tests?
5. Rapid HIV Testing Increases Possibility of Treatment
6. Rapid Response was Crucial to Containing the 1918 Flu Pandemic
7. West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak
8. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
9. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
10. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
11. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... India , May 6, 2016 ... numbers of liver disorders along with rise in ... steatohepatitis) drugs in the coming few years. The ... over last five years on account of rising ... steatohepatitis) is a large, un-tapped market with no ...
(Date:5/5/2016)... First quarter 2016 adjusted diluted earnings per share (EPS) of ... First quarter reported diluted (GAAP) loss per share from continuing ... financial guidance; now expects 2016 revenues to range from $3.87 ... per share to range from $4.50 to $4.80 ... facility restructuring , Company expands Board capabilities, ...
(Date:5/5/2016)... 2016 Research and Markets has announced the ... 5 EU Markets"  report to their offering.  ,     (Logo: ... on the current Positron Emission Tomography (PET) scanner and cyclotron ... which includes France , Germany ... and the United Kingdom . ...
Breaking Medicine Technology:
(Date:5/6/2016)... ... May 06, 2016 , ... Norwood Insurance Group, ... latest beneficiary of their ongoing community enrichment program. The current campaign is being ... McGaughey faces many more months of treatments, leaving his family in great need ...
(Date:5/6/2016)... ... May 06, 2016 , ... DrugDev President and CEO ... the pharmaceutical industry conducts clinical trials. This month Ibs was named No. 20 on ... and he was honored as a Tech Disruptor by the Philadelphia Business Journal. , ...
(Date:5/6/2016)... ... 06, 2016 , ... Featured cast and producers of the ... at the 2016 Learning Summit , June 12-15, in Paradise Valley, Arizona. ... stories—of complicated family issues, financial difficulties, and other personal obstacles—are the stories of ...
(Date:5/6/2016)... ... ... wide variety of national pet product manufacturers, companies and brands will gather for one day ... from noon to 8 p.m. at New York City’s Roger Smith Hotel. The event is ... outdoor and safety pet products in today’s marketplace. , Petrend Event showcases the ...
(Date:5/6/2016)... ... May 06, 2016 , ... Innovations with Ed ... airing third quarter 2016, via Discovery Channel. Dates and show times TBA. , ... optimized drug discovery through innovative cellular analysis. In this segment, viewers will learn ...
Breaking Medicine News(10 mins):